デフォルト表紙
市場調査レポート
商品コード
1600911

心不全治療薬市場:治療、タイプ、ステージ、エンドユーザー別-2025年~2030年の世界予測

Heart Failure Therapeutics Market by Treatment (Medical Devices, Medicines, Surgery), Type (Diagnosis, Prognosis), Stage, End User - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 186 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.91円
心不全治療薬市場:治療、タイプ、ステージ、エンドユーザー別-2025年~2030年の世界予測
出版日: 2024年10月31日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心不全治療薬市場は、2023年に239億8,000万米ドルと評価され、2024年には261億6,000万米ドルに達すると予測され、CAGR 10.46%で成長し、2030年には481億3,000万米ドルに達すると予測されています。

心不全治療薬市場には、心臓が十分な血液を送り出せない慢性疾患である心不全の管理を目的とした幅広い治療オプションが含まれ、世界全体で数百万人が影響を受けています。この市場には、医薬品、医療機器、遺伝子治療などの革新的治療が含まれ、症状の緩和や患者のQOLの向上を目的としています。心不全治療薬の必要性は、心血管疾患の有病率の増加、人口の高齢化、肥満や糖尿病などのライフスタイルに関連した危険因子の罹患率の上昇によってもたらされています。用途は急性期病院から慢性期外来医療まで幅広く、最終用途は病院、診療所、外来医療センター、在宅医療に広がっています。主な成長要因としては、診断および治療方法における技術的進歩、進行中の研究および臨床試験、新薬の強力なパイプラインなどが挙げられます。さらに、政府の取り組みや医療費の増加が市場の成長をさらに後押ししています。新たなビジネスチャンスは、個別化医療と、有効性と患者のアドヒアランスの向上を約束する新規ドラッグデリバリーシステムの開発にあります。また、創薬開発のための製薬企業と研究機関の共同研究も重要な機会です。しかし、市場開拓は、高い治療費、厳しい規制当局の承認、長い薬剤開発サイクルといった課題に直面しています。さらに、ジェネリック医薬品メーカーとの競合が収益性を阻害する可能性もあります。こうした障壁を克服するために、業界はバイオマーカーの同定、創薬への人工知能の活用、患者中心のケアモデルの強化など、革新的な研究に注力すべきです。市場力学は競争と協調が混在するダイナミックな市場であり、持続的な発展のためには研究開発への戦略的投資が必要です。価値観に基づくケアモデルを取り入れ、承認プロセスを合理化するための政策改革を推し進めることが成長を活性化する可能性があり、ヘルスケア利害関係者にこの拡大する分野に参入するチャンスを提供します。

主な市場の統計
基準年[2023] 239億8,000万米ドル
予測年[2024] 261億6,000万米ドル
予測年[2030] 481億3,000万米ドル
CAGR(%) 10.46%

市場力学:急速に進化する心不全治療薬市場の主要市場インサイトを公開

心不全治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 老年人口における心血管疾患の有病率の上昇
    • ライフスタイルの変化による心不全および不整脈への感受性の高まり
    • 心不全の早期診断と早期管理の可能性と嗜好性
  • 市場抑制要因
    • 心不全治療に関する高コストと償還の問題
  • 市場機会
    • 心不全治療薬におけるイノベーションと開発
    • 政府の継続的な取り組みと民間セクターによる投資の増加
  • 市場の課題
    • 心不全状態の管理に関する懸念

ポーターの5つの力:心不全治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:心不全治療薬市場における外部からの影響の把握

外部マクロ環境要因は、心不全治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析心不全治療薬市場における競合情勢の把握

心不全治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス心不全治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、心不全治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています:

1.市場の浸透度:業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 高齢者人口における心血管疾患の罹患率の上昇
      • ライフスタイルの変化により心不全や不整脈に対する感受性が高まっている
      • 心不全の早期診断と管理の可用性と好み
    • 抑制要因
      • 心不全治療に関連する高額な費用と償還の問題
    • 機会
      • 心不全治療薬におけるイノベーションと開発
      • 政府の継続的な取り組みと民間セクターによる投資の増加
    • 課題
      • 心不全状態の管理に関する懸念
  • 市場セグメンテーション分析
    • 治療:心臓の健康管理のために処方薬や個別化医薬品を利用する消費者が急増
    • タイプ:診断ツールと予後の革新は心臓の健康状態をより良く管理するのに役立ちます
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境
  • 顧客のカスタマイズ

第6章 心不全治療薬市場:治療別

  • 医療機器
    • 二段階正圧空気装置
    • 両室ペースメーカー
    • 持続陽圧呼吸装置
    • 心臓ポンプ
    • 植込み型除細動器
    • 埋め込み型左心室補助装置
    • アンジオテンシンII受容体遮断薬
    • 抗凝固薬
    • 抗血小板薬
    • 血圧維持剤
    • 利尿剤
    • 硝酸塩
    • スタチン
  • 手術
    • 心臓再同期
    • 冠動脈バイパス移植
    • 冠動脈血行再建術
    • 心臓移植
    • 心臓弁置換術

第7章 心不全治療薬市場:タイプ別

  • 診断
  • 予後

第8章 心不全治療薬市場:ステージ別

  • ステージA
  • ステージB
  • ステージC
  • ステージD

第9章 心不全治療薬市場:エンドユーザー別

  • クリニック
  • 病院
  • 医療研究機関

第10章 南北アメリカの心不全治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第11章 アジア太平洋の心不全治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第12章 欧州・中東・アフリカの心不全治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第13章 競合情勢

  • 市場シェア分析、2023年
  • FPNVポジショニングマトリックス、2023年
  • 競合シナリオ分析
    • FDA、心不全に対する遺伝子治療薬AB-1002にファストトラック承認を付与
    • ノボノルディスクがカーディオールファーマシューティカルズを買収、RNAを標的としたイノベーションで心不全治療ポートフォリオを拡大
    • 米国FDA、メドトロニックの心臓病治療システムを承認
    • J&J、脳卒中を軽減する新型心臓インプラントの買収に4億米ドルを投じる
    • FDA、心臓収縮力調節装置によるMRIの使用を承認

企業一覧

  • Cardiol Therapeutics Inc.
  • Johnson & Johnson Services, Inc.
  • Verve Therapeutics, Inc.
  • Impulse Dynamics
  • Abbott Laboratories
  • Jarvik Heart, Inc.
  • Berlin Heart GmbH
  • Dr. Reddy's Laboratories Limited
  • Amgen Inc.
  • Glenmark Pharmaceuticals Limited
  • Alembic Pharmaceuticals Limited
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Medtronic PLC
  • Orion Corporation
  • Eli Lilly and Company
  • LivaNova, PLC
  • Cipla Limited
  • Novo Nordisk A/S
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Boston Scientific Corporation
  • Merck & Co., Inc.
  • Beckman Coulter, Inc.
  • Bayer AG
  • Osypka Medical GmbH
  • Biosensors International Group, Ltd.
  • Pfizer, Inc.
  • Biotronik SE & Co. KG
  • Novartis AG
図表

LIST OF FIGURES

  • FIGURE 1. HEART FAILURE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HEART FAILURE THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEART FAILURE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEART FAILURE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEART FAILURE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEART FAILURE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BI-LEVEL POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BIVENTRICULAR PACEMAKER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CONTINUOUS POSITIVE AIR PRESSURE DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART PUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE LEFT VENTRICULAR ASSIST DEVICE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANGIOTENSIN II RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTICOAGULANT MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY ANTIPLATELET MEDICINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY BLOOD PRESSURE MAINTAINING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY NITRATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CARDIAC RESYNCHRONIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY ARTERY BYPASS GRAFTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CORONARY REVASCULARIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HEART VALVE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE D, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 243. NETHERLANDS HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 248. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 250. NIGERIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 255. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 257. NORWAY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 262. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 264. POLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 269. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 271. QATAR HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 276. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 278. RUSSIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 283. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 285. SAUDI ARABIA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 290. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 292. SOUTH AFRICA HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 297. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 299. SPAIN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 304. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 306. SWEDEN HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 311. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 313. SWITZERLAND HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 317. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 318. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 320. TURKEY HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY STAGE, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED ARAB EMIRATES HEART FAILURE THERAPEUTICS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICAL DEVICES, 2018-2030 (USD MILLION)
  • TABLE 330. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY MEDICINES, 2018-2030 (USD MILLION)
  • TABLE 331. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY SURGERY, 2018-2030 (USD MILLION)
  • TABLE 332. UNITED KINGDOM HEART FAILURE THERAPEUTICS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)

TAB

目次
Product Code: MRR-430D42AA0D2E

The Heart Failure Therapeutics Market was valued at USD 23.98 billion in 2023, expected to reach USD 26.16 billion in 2024, and is projected to grow at a CAGR of 10.46%, to USD 48.13 billion by 2030.

The heart failure therapeutics market encompasses a wide range of treatment options aimed at managing heart failure, a chronic condition marked by the heart's inability to pump sufficient blood, which affects millions globally. The scope of this market includes pharmaceuticals, medical devices, and other innovative treatments like gene therapy, designed to alleviate symptoms and improve patient quality of life. The necessity for heart failure therapeutics is driven by the increasing prevalence of cardiovascular diseases, an aging population, and the rising incidence of lifestyle-related risk factors such as obesity and diabetes. Applications range from acute hospital settings to chronic outpatient care, with end-use spread across hospitals, clinics, ambulatory care centers, and home healthcare. Key growth influencers include technological advancements in diagnostic and treatment modalities, ongoing research and clinical trials, and a strong pipeline of new drugs. Moreover, government initiatives and increased healthcare expenditure further augment market growth. Emerging opportunities lie in personalized medicine and the development of novel drug delivery systems, which promise improved efficacy and patient adherence. Collaborations between pharmaceutical companies and research institutions for drug discovery and development are also vital opportunities. However, market growth faces challenges such as high treatment costs, stringent regulatory approvals, and long drug development cycles. Additionally, competition from generic drug manufacturers can hamper profitability. To overcome these barriers, the industry should focus on innovative research in biomarker identification, utilizing artificial intelligence for drug discovery, and enhancing patient-centric care models. The heart failure therapeutics market is dynamic with a blend of competition and collaboration, necessitating strategic investment in R&D for sustained progress. Embracing value-based care models and pushing for policy reforms to streamline approval processes could vitalize growth, offering healthcare stakeholders a chance to tap into this expanding field.

KEY MARKET STATISTICS
Base Year [2023] USD 23.98 billion
Estimated Year [2024] USD 26.16 billion
Forecast Year [2030] USD 48.13 billion
CAGR (%) 10.46%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Heart Failure Therapeutics Market

The Heart Failure Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
    • Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
    • Availability and Preferences of Early Diagnosis and Management for Heart Failure
  • Market Restraints
    • High Cost and Reimbursement Issues Related to Heart Failure Treatment
  • Market Opportunities
    • Innovations and Development in the Heart Failure Therapeutics
    • Ongoing Government Initiatives and Increasing Investments by Private Sectors
  • Market Challenges
    • Concerns Related to Management of Heart Failure Condition

Porter's Five Forces: A Strategic Tool for Navigating the Heart Failure Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Heart Failure Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Heart Failure Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Heart Failure Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Heart Failure Therapeutics Market

A detailed market share analysis in the Heart Failure Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Heart Failure Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Heart Failure Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Heart Failure Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Cardiol Therapeutics Inc., Johnson & Johnson Services, Inc., Verve Therapeutics, Inc., Impulse Dynamics, Abbott Laboratories, Jarvik Heart, Inc., Berlin Heart GmbH, Dr. Reddy's Laboratories Limited, Amgen Inc., Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Medtronic PLC, Orion Corporation, Eli Lilly and Company, LivaNova, PLC, Cipla Limited, Novo Nordisk A/S, GlaxoSmithKline PLC, AstraZeneca PLC, Boston Scientific Corporation, Merck & Co., Inc., Beckman Coulter, Inc., Bayer AG, Osypka Medical GmbH, Biosensors International Group, Ltd., Pfizer, Inc., Biotronik SE & Co. KG, and Novartis AG.

Market Segmentation & Coverage

This research report categorizes the Heart Failure Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across Medical Devices, Medicines, and Surgery. The Medical Devices is further studied across Bi-level positive air pressure device, Biventricular Pacemaker, Continuous Positive Air Pressure Device, Heart Pumps, Implantable Cardioverter-Defibrillators, and Implantable Left Ventricular Assist Device. The Medicines is further studied across Angiotensin II Receptor Blockers, Anticoagulant Medicines, Antiplatelet Medicines, Blood Pressure Maintaining Agents, Diuretics, Nitrates, and Statins. The Surgery is further studied across Cardiac Resynchronization, Coronary Artery Bypass Grafting, Coronary Revascularization, Heart Transplant, and Heart Valve Replacement.
  • Based on Type, market is studied across Diagnosis and Prognosis.
  • Based on Stage, market is studied across Stage A, Stage B, Stage C, and Stage D.
  • Based on End User, market is studied across Clinic, Hospital, and Medical Research Organization.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
      • 5.1.1.2. Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
      • 5.1.1.3. Availability and Preferences of Early Diagnosis and Management for Heart Failure
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost and Reimbursement Issues Related to Heart Failure Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations and Development in the Heart Failure Therapeutics
      • 5.1.3.2. Ongoing Government Initiatives and Increasing Investments by Private Sectors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns Related to Management of Heart Failure Condition
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Treatment: Extensive consumers shift toward prescribed and personalized medicines for heart health management
    • 5.2.2. Type: Innovations in the diagnostic tools and prognosis helps in better managing the heart health condition
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Heart Failure Therapeutics Market, by Treatment

  • 6.1. Introduction
  • 6.2. Medical Devices
    • 6.2.1. Bi-level positive air pressure device
    • 6.2.2. Biventricular Pacemaker
    • 6.2.3. Continuous Positive Air Pressure Device
    • 6.2.4. Heart Pumps
    • 6.2.5. Implantable Cardioverter-Defibrillators
    • 6.2.6. Implantable Left Ventricular Assist Device
  • 6.3. Medicines
    • 6.3.1. Angiotensin II Receptor Blockers
    • 6.3.2. Anticoagulant Medicines
    • 6.3.3. Antiplatelet Medicines
    • 6.3.4. Blood Pressure Maintaining Agents
    • 6.3.5. Diuretics
    • 6.3.6. Nitrates
    • 6.3.7. Statins
  • 6.4. Surgery
    • 6.4.1. Cardiac Resynchronization
    • 6.4.2. Coronary Artery Bypass Grafting
    • 6.4.3. Coronary Revascularization
    • 6.4.4. Heart Transplant
    • 6.4.5. Heart Valve Replacement

7. Heart Failure Therapeutics Market, by Type

  • 7.1. Introduction
  • 7.2. Diagnosis
  • 7.3. Prognosis

8. Heart Failure Therapeutics Market, by Stage

  • 8.1. Introduction
  • 8.2. Stage A
  • 8.3. Stage B
  • 8.4. Stage C
  • 8.5. Stage D

9. Heart Failure Therapeutics Market, by End User

  • 9.1. Introduction
  • 9.2. Clinic
  • 9.3. Hospital
  • 9.4. Medical Research Organization

10. Americas Heart Failure Therapeutics Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Heart Failure Therapeutics Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Heart Failure Therapeutics Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Grants Fast Track Status to AB-1002 Gene Therapy for Heart Failure
    • 13.3.2. Novo Nordisk to Acquire Cardior Pharmaceuticals, Expanding Heart Failure Therapeutic Portfolio with RNA-Targeted Innovations
    • 13.3.3. US FDA approves Medtronic's system for heart condition
    • 13.3.4. J&J drops USD 400 million to acquire new type of stroke-reducing heart implant
    • 13.3.5. FDA Clears MRI Use with Cardiac Contractility Modulation Device

Companies Mentioned

  • 1. Cardiol Therapeutics Inc.
  • 2. Johnson & Johnson Services, Inc.
  • 3. Verve Therapeutics, Inc.
  • 4. Impulse Dynamics
  • 5. Abbott Laboratories
  • 6. Jarvik Heart, Inc.
  • 7. Berlin Heart GmbH
  • 8. Dr. Reddy's Laboratories Limited
  • 9. Amgen Inc.
  • 10. Glenmark Pharmaceuticals Limited
  • 11. Alembic Pharmaceuticals Limited
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Bristol-Myers Squibb Company
  • 14. Medtronic PLC
  • 15. Orion Corporation
  • 16. Eli Lilly and Company
  • 17. LivaNova, PLC
  • 18. Cipla Limited
  • 19. Novo Nordisk A/S
  • 20. GlaxoSmithKline PLC
  • 21. AstraZeneca PLC
  • 22. Boston Scientific Corporation
  • 23. Merck & Co., Inc.
  • 24. Beckman Coulter, Inc.
  • 25. Bayer AG
  • 26. Osypka Medical GmbH
  • 27. Biosensors International Group, Ltd.
  • 28. Pfizer, Inc.
  • 29. Biotronik SE & Co. KG
  • 30. Novartis AG